Mononucleosis medical therapy

Jump to navigation Jump to search

Mononucleosis Microchapters

Home

Patient Information

Overview

Pathophysiology

Epidemiology and Demographics

Risk Factors

Causes

Differentiating Mononucleosis from other Diseases

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Mononucleosis medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Mononucleosis medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Mononucleosis medical therapy

CDC on Mononucleosis medical therapy

Mononucleosis medical therapy in the news

Blogs on Mononucleosis medical therapy

Directions to Hospitals Treating Mononucleosis

Risk calculators and risk factors for Mononucleosis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Infectious mononucleosis is generally self-limiting and only symptomatic and/or supportive treatments are used. However, severe tonsillar enlargement may cause life-threatening airway obstruction and therefore, close monitoring of such high-risk patients is essential. Glucocorticoids may be indicated in such cases of severe airway obstruction. Acyclovir has been tried as they decrease oropharyngeal viral shedding. Recently, valacyclovir has shown to lower or eliminate the presence of the Epstein-Barr virus in subjects afflicted with acute mononucleosis, leading to a significant decrease in the severity of symptoms.

Medical Therapy

Supportive Therapy

  • Infectious mononucleosis is generally self-limiting and only symptomatic and/or supportive treatments are used.[1]
  • Rest is recommended during the acute phase of the infection, but activity should be resumed once acute symptoms have resolved (~3 weeks).
  • Contact sports or heavy physical activity should be avoided for a minimum 6-8 weeks or until splenomegaly has resolved as determined by ultrasound scan, to abrogate the risk of splenic rupture which is a common complication among these patients.[1]

Pharmacotherapy

  • There is little evidence to support the use of acyclovir, although it may reduce initial oropharyngeal viral shedding.[5] However, the antiviral drug valacyclovir has recently been shown to lower or eliminate the presence of the Epstein-Barr virus in subjects afflicted with acute mononucleosis, leading to a significant decrease in the severity of symptoms.[6][7][8]
  • Antibiotics are not used as they are ineffective against viral infections. The antibiotics amoxicillin and ampicillin are contraindicated in the case of any coinciding bacterial infections during mononucleosis because their use can frequently precipitate a non-allergic rash.

References

  1. 1.0 1.1 Beers MH, Porter RS, Jones TV, Kaplan JL, Berkwits M, editors., eds. (2006). The Merck manual of diagnosis and therapy (18th ed. ed.). Whitehouse Station (NJ): Merck Research Laboratories. ISBN 0-911910-18-2.
  2. Candy B, Hotopf M. (2006). "Steroids for symptom control in infectious mononucleosis". Cochrane Database Sys Rev (4): CD004402. doi:10.1002/14651858.CD004402.pub2. PMID 16856045.
  3. 3.0 3.1 Antibiotic Expert Group. Therapeutic guidelines: Antibiotic. 13th ed. North Melbourne: Therapeutic Guidelines; 2006.
  4. "Infectious Mononucleosis". WebMD. Jan 24, 2006. Retrieved 2006-07-10.
  5. Torre D, Tambini R (1999). "Acyclovir for treatment of infectious mononucleosis: a meta-analysis". Scand. J. Infect. Dis. 31 (6): 543–7. PMID 10680982.
  6. Balfour HH, Hokanson KM, Schacherer RM; et al. (2007). "A virologic pilot study of valacyclovir in infectious mononucleosis". J. Clin. Virol. 39 (1): 16–21. doi:10.1016/j.jcv.2007.02.002. PMID 17369082.
  7. Simon; et al. (2003). "The Effect of Valacyclovir and Prednisolone in Reducing Symptoms of EBV Illness In Children: A Double-Blind, Placebo-Controlled Study". International Pediatrics. 18 (3): 164–169. Unknown parameter |month= ignored (help)
  8. Balfour HH, Hokanson KM, Schacherer RM; et al. (2007). "A virologic pilot study of valacyclovir in infectious mononucleosis". J. Clin. Virol. 39 (1): 16–21. doi:10.1016/j.jcv.2007.02.002. PMID 17369082.


Template:WikiDoc Sources